



## David Lu

### Partner

Boston  
+1.617.261.3252

David.Lu@klgates.com

## OVERVIEW

David Lu is a partner in the firm's Intellectual Property practice group.

## PROFESSIONAL BACKGROUND

David focuses his practice on patent prosecution, strategic intellectual property counseling, and due diligence for life science industries. He has designed global patent strategies in the field of pharmaceuticals and biotechnology, and managed large patent portfolios for a variety of clients. David's clients range from international corporations, mid-sized biotech companies, to venture capital funded startups.

David has handled matters in a numerous technology areas, including cancer therapies, genome technologies, gene therapies, antibody drugs, personalized medicine, RNA therapeutics, diagnostic methods, and medical devices. By identifying each client's technology strengths and business goals, David provides customized and creative legal solutions.

Prior to joining the firm, David served as a partner and the co-lead of the life sciences group at a U.S. law firm.

## ACHIEVEMENTS

- Selected to Massachusetts Rising Stars for Intellectual Property (2019-2023)
- National Institute of Health (NIH) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship (2007-2008)

## PROFESSIONAL / CIVIC ACTIVITIES

- Member, Boston Patent Law Association (BPLA)
- Member, Asian American Lawyers Association of Massachusetts (AALAM)
- Member, Duke Boston Regional Board
- Leadership Councils, Health Care and Life Sciences, Greater Boston Chamber of Commerce

## SPEAKING ENGAGEMENTS

- “The Three Pillars of Your Patent Prosecution: Innovation, Insights & Strategy,” CenterForce IP Strategy Series, Boston, MA, 15 June 2023

## EDUCATION

- J.D., Suffolk University Law School, 2013 (*Intellectual Property Law Concentration with Distinction*)
- Ph.D., Duke University, 2004 (*Molecular Genetics and Microbiology*)
- M.S., Fudan University, (*Genetics*)
- B.S., Fudan University, (*Biochemistry*)
- Certificate, Duke University, 2004 (*Bioinformatics and Genome Technology*)

## ADMISSIONS

- Bar of Massachusetts
- United States Patent and Trademark Office
- United States Court of Appeals for the Federal Circuit

## LANGUAGES

- Chinese (Mandarin)
- English
- Shanghainese

## OTHER PUBLICATIONS

- Co-author, Physiological modulation of endogenous BRCA1 p220 abundance suppresses DNA damage during the cell cycle. *Genes Dev.* 27(20): 2274-91. (2013)
- Co-author, Further evidence for BRCA1 communication with the inactive X chromosome. *Cell* 128(5): 998-1002. (2007)
- Co-author, Epstein-Barr Virus microRNAs are evolutionarily conserved and differentially expressed. *PLoS Pathog.* 2(3):e23. (2006)
- Co-author, Kaposi's sarcoma associated herpesvirus expresses an array of novel viral microRNAs in latently infected cells. *Proc. Natl. Acad. Sci. U S A* 102(15): 5570-75. (2005)

- Co-author, Adenovirus VA1 non-coding RNA can inhibit small interfering and microRNA biogenesis and function. *Journal of Virology* 78(23): 12868-76. (2004)
- Co-author, Nonsense mediated decay induced by tethered human UPF3B is restricted to the cytoplasm. *RNA Biology* 1(1): 42-47. (2004)
- Co-author, Exon junction complexes mediate the enhancing effect of splicing on mRNA expression. *Proc. Natl. Acad. Sci. U S A* 100(20): 11327-32. (2003)
- Co-author, Analysis of the stimulatory effect of splicing on mRNA production and utilization in mammalian cells. *RNA* 9(5): 618-30. (2003)

## NEWS & EVENTS

- 9 March 2022, K&L Gates Continues IP Practice Growth, Bolsters Pharma, Biotech Capabilities with Addition of 10-Person Patent Team in Boston

## AREAS OF FOCUS

- IP Procurement and Portfolio Management

## INDUSTRIES

- Health Care Sector
- Life Sciences
- Manufacturing
- Pharmaceuticals, Biologics, and Medical Devices